Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 26:12:676525.
doi: 10.3389/fneur.2021.676525. eCollection 2021.

Efficacy and Safety of Moxibustion for Postherpetic Neuralgia: A Systematic Review and Meta-Analysis

Affiliations

Efficacy and Safety of Moxibustion for Postherpetic Neuralgia: A Systematic Review and Meta-Analysis

Qiqi Wu et al. Front Neurol. .

Abstract

Background: Postherpetic neuralgia (PHN) is one of the most common complications of herpes zoster (HZ), and there is still a lack of effective therapies. An increasing number of studies have found that compared to traditional therapy, moxibustion treatment is beneficial for the treatment of PHN, although current evidence remains inconclusive. This systematic review and meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the efficacy and safety of moxibustion for PHN. Methods: We conducted a broad literature review of a range of databases from inception to December 2020, including the Cochrane Library, PubMed, EMBASE, Web of Science, Clinical Trails, China National Knowledge Infrastructure (CNKI), VIP Database for Chinese Technical Periodicals (VIP), China Biomedical Network Information, and Wanfang databases. We included RCTs that compared moxibustion to pharmacological therapies, herbal medicine, or no treatment for treating PHN. The main outcome measure was efficacy rate and Visual Analog Scale (VAS); the secondary outcome measure was adverse events. Data accumulation and synthesis included meta-analysis, publication bias, sensitivity analysis, risk-of-bias assessment, and adverse events. Results: We included 13 RCTs involving 798 patients. Compared with the controls (pharmacological therapies, herbal medicine, or no treatment), moxibustion achieved a significantly higher efficacy rate (odds ratio [OR]: 3.65; 95% [confidence interval]: [2.32, 5.72]; P < 0.00001). Subgroup analysis of the distinct moxibustion modalities showed that both Zhuang medicine medicated thread and thunder-fire moxibustions obtained higher clinical efficacy than the control group. Compared with the controls, moxibustion resulted in significantly lower scores on the VAS (Weighted Mean Difference (MD) = -1.79; 95% CI: [-2.26, -1.33]; P < 0.00001). However, there was no significant difference in terms of safety between moxibustion and the controls (OR = 0.33; 95% CI [0.06, 1.77]; P = 0.19). Conclusion: Due to the lack of methodological quality as well as the significant heterogeneity of the included studies, it remains difficult to draw a firm conclusion on the efficacy and safety of moxibustion for the treatment of PHN. Future high-quality studies are urgently needed.

Keywords: herpes zoster; meta-analysis; moxibustion; postherpetic neuralgia; systematic reveiw.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of the process used to retrieve relevant articles from the literature.
Figure 2
Figure 2
An evaluation of risk bias in the included randomized controlled trials (RCTs).
Figure 3
Figure 3
Forest plot and meta-analysis of the clinical efficacy rate of moxibustion in the treatment of PHN.
Figure 4
Figure 4
Subgroup analysis of different interventions in the control groups.
Figure 5
Figure 5
Subgroup analysis of different treatment courses.
Figure 6
Figure 6
Subgroup analysis of the different modalities used for moxibustion treatment.
Figure 7
Figure 7
Meta-analysis of VAS data.
Figure 8
Figure 8
Meta-analysis of adverse events.
Figure 9
Figure 9
Funnel plot of publication bias.

Similar articles

Cited by

References

    1. Hoshi SL, Seposo X, Shono A, Okubo L, Kondo M. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herps zoster and post-herpetic neuralgia among adults aged 65 and over in Japan. Vaccine. (2019) 37:3588–97. 10.1016/j.vaccine.2019.05.006 - DOI - PubMed
    1. Jones J. Postherpetic neuralgia. J Pain Palliat Care Pharmacother. (2015) 29:180–1. 10.3109/15360288.2015.1037520 - DOI - PubMed
    1. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. (2014) 4:e004833. 10.1136/bmjopen-2014-004833 - DOI - PMC - PubMed
    1. Schmader K. Herpes Zoster. Ann Intern Med. (2018) 169:897. 10.7326/L18-0558 - DOI - PubMed
    1. Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Mansfield K, et al. . Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: a cohort study. Neurology. (2016) 87:94–102. 10.1212/WNL.0000000000002808 - DOI - PMC - PubMed

Publication types

LinkOut - more resources